LEO Pharma's Profitability Surges as Dermatology Portfolio Drives Growth
Event summary
- LEO Pharma achieved 10% constant exchange rate (CER) revenue growth in 2025, exceeding guidance.
- Adjusted EBITDA margin more than doubled to 16%, resulting in a DKK 2,107 million profit.
- Revenue growth was led by North America (+35% CER), with key dermatology brands like Anzupgo® and Spevigo® contributing to a 48% revenue increase.
- The company returned to positive net profit (DKK 2,489 million) and generated DKK 1,875 million in free cash flow.
The big picture
LEO Pharma's strong performance reflects a successful strategic pivot towards dermatology, capitalizing on the growing demand for specialized treatments. The acquisition of Spevigo® and the U.S. launch of Anzupgo® demonstrate a willingness to expand through both organic innovation and strategic partnerships. The company's return to profitability after a period of losses signals a potential inflection point, but continued execution will be vital to maintaining this momentum in a competitive pharmaceutical landscape.
What we're watching
- Growth Sustainability
- The continued reliance on North American growth raises questions about geographic diversification and potential saturation risks as the company expands globally.
- Margin Pressure
- While margins improved significantly, the planned increase in commercial and R&D investments could compress profitability if revenue growth slows.
- Pipeline Execution
- The success of late-stage trials for Anzupgo® and Spevigo® will be critical to sustaining the current growth trajectory and justifying ongoing investment in innovation.
Related topics